Non-obese diabetic (NOD) mice provide a model for type 1 diabetes mellitus. We previously showed that allogeneic bone marrow transplantation (ABMT) can prevent and treat insulitis and overt diabetes in NOD mice. However, ABMT alone could not be used to treat overt diabetes in NOD mice whose islets had been completely destroyed. To provide insulin-producing cells, pancreatic tissue from newborn mice was grafted under the renal capsules in combination with ABMT. The aims of concomitant ABMT are as follows. (i) It induces immunological tolerance to the donor-type major histocompatibility complex determinants and permits the host to accept subsequent pancreatic allografts from the bone marrow donor. (ii) ABMT replaces abnormal stem cells with normal stem cells. After transplantation of bone marrow plus newborn pancreas, NOD mice showed reduction of the glycosuria and a normal response in the glucose-tolerance test. Immunohistological study revealed the presence of clustered insulin-containing beta cells in the grafted pancreatic transplants. ABMT may become a viable treatment of established type 1 diabetes mellitus in humans.
It is thought that autoimmune mechanisms are involved in the etiopathogenesis of type 1 diabetes mellitus: humoral and cellular autoimmune responses specific for insulin-producing beta cells in both humans and animal models have been well documented (1) (2) (3) .
Experiments using BB rats, which spontaneously develop autoimmune insulitis resulting in type 1 diabetes mellitus, have contributed to the elucidation of the etiopathogenesis of diabetes and also to identification of rational therapy (4) . It has been reported that diabetes in BB rats can be adoptively transferred to both young BB rats and diabetes-resistant rats when concanavalin A-activated spleen cells of BB rats with overt diabetes are introduced into these rats (5, 6) . In reverse, allogeneic bone marrow transplantation (ABMT) from normal rats into BB rats has prevented diabetes (7). These observations suggest that abnormal immunocompetent cells are responsible for the development of type 1 diabetes, and that ABMT, which replaces these abnormal stem cells with stem cells from normal bone marrow, has prophylactic and curative effects in BB rats.
Another animal model for type 1 diabetes, the non-obese diabetic (NOD) mouse, was established by Makino et al. (8) . More than 90% of both male and female NOD mice develop insulitis by the age of 200 days. This is followed by overt diabetes that has been shown to be due to the destruction of beta cells in the pancreatic islets in 80% of the females and 20% of the males by the age of 210 days. Non-treated NOD mice die within 1 month of the development of glycosuria.
In a previous report (9) , we demonstrated that ABMT could be used to treat autoimmune insulitis and prevent overt diabetes in NOD mice but that ABMT alone could not cure established diabetes. This is because the beta cells of the islets are already destroyed by the time the disease is established. More recently, we found that mice which underwent liver allografts combined with ABMT accept donortype as well as host-type liver tissue (10), prompting us to treat type 1 diabetes mellitus in NOD mice by ABMT followed by pancreatic allografts. In the present study, we provide evidence that bone marrow plus pancreas transplantation can be used to treat type 1 diabetes mellitus in NOD mice.
MATERIALS AND METHODS
Mice. The NOD mice were bred and maintained under specific pathogen-free conditions in our animal facilities. Female 
RESULTS
Five of the seven treated NOD mice showed an improvement in glycosuria and survived more than 30 days after pancreatic transplants; four have survived more than 90 days, and one is still alive 365 days (at the time of writing) after pancreatic transplants (Table 1) . By contrast, control NOD mice with overt diabetes died within 2 weeks unless they had been treated with insulin.
As shown in Fig. 1 , control NOD mice with glycosuria showed an abnormal response in the glucose-tolerance test, whereas the NOD mice that had been operated on showed a mg/dl such treated NOD mice, the immunoreactive insulin content being 20.3-31.0 ,ug/ml after a 14-hr fast. Grafted islets were found under the renal capsules of the NOD mice (Fig. 2 Left) . Immunohistochemical study revealed the presence of clustered insulin-producing beta cells in the islets (Fig. 2 Right) .
DISCUSSION
The results show that pancreatic tissue grafts combined with ABMT can be used to treat overt diabetes mellitus in NOD mice. The aims of the concomitant ABMT are as follows: (i) ABMT induces immunological tolerance to the donor-type major histocompatibility complex-encoded determinants and permits the host to accept subsequent allogeneic pancreatic grafts from the bone marrow donor and (ii) ABMT replaces abnormal stem cells with normal stem cells following the preparative lethal whole-body irradiation, thus eliminating the danger of a recurrence of diabetes.
Total lymphoid irradiation and immunosuppressive agents such as azathioprine, cyclophosphamide, anti-lymphocyte globulin, and more recently cyclosporine have been used not only to treat autoimmune diseases, including organ-specific autoimmune diseases, but also to prevent the rejection of other organ allografts. However, these approaches exert cytotoxic effects on lymphocytes, especially T cells, and patients undergoing these therapies over long periods often suffer from life-threatening infections and cancers attributable to the immunodeficiency. In contrast to these approaches, pancreatic allografts combined with ABMT have been shown in the present study to have no harmful side effects in mice. Furthermore, we have found, using animal models for systemic autoimmune diseases, that the immunological functions of T cells, B cells, and macrophages can be normalized after ABMT and that the renal damage characteristic of these diseases can also be ameliorated after ABMT (S.I., R.Y., Takao Nakamura, Ken'ichi Sekita, M.I., Shozo Izui, Kyoko Hayakawa, Junko Toki, K.S., H.I., Y.H., and R.A.G., unpublished observation).
These findings suggest that fetal pancreatic allografts in conjunction with transplantation of fetal liver cells as a source of hemopoietic stem cells from the same aborted fetus may become a viable treatment of type 1 diabetes and possibly some forms of type 2 diabetes. However, it remains to be determined what triggers these autoimmune responses and how it is that ABMT can cure insulitis. Further analysis at the genetic and molecular levels will be necessary to clarify the exact mechanism of the development of type 1 diabetes mellitus.
